Letters to the Editor

Patients’ experience and tolerability with canakinumab and anakinra for the treatment of adult-onset Still’s disease

C. Campochiaro¹, N. Farina², A. Tomelleri³, G. De Luca⁴, G. Cavalli⁵, L. Dagna⁶

Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, and Vita-Salute San Raffaele University, Milan, Italy. campochiaro.corrado@hsr.it
Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, and Vita-Salute San Raffaele University, Milan, Italy.
Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, and Vita-Salute San Raffaele University, Milan, Italy.
Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, and Vita-Salute San Raffaele University, Milan, Italy.
Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, and Vita-Salute San Raffaele University, Milan, Italy.
Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, and Vita-Salute San Raffaele University, Milan, Italy.

CER15233
2022 Vol.40, N°8
PI 1598, PF 1599
Letters to the Editor

Free to view
(click on article PDF icon to read the article)

PMID: 35349406 [PubMed]

Received: 12/10/2021
Accepted : 15/11/2021
In Press: 18/03/2022
Published: 15/09/2022